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Opioid addiction has been on the rise since 1990, when physicians began administering 
prescription pain medications. The population has undergone a drastic change from opioid 
prescriptions such as oxycodone to illicit forms, such as heroin, to aid pain management. Illegal 
opiates became the alternative drug at a lower cost to fulfill cravings and dependence that 
prescriptions may no longer feed. With a rise in dependence, pharmaceutical laboratories 
developed medicated assistant treatments (MAT) to aid in this crisis, more formally known as 
buprenorphine and methadone. Studies conducted show evidence of a decrease in illicit opioid 
use when using these medicated treatments and can lead to successful retention of the addiction. 
The users' experiences are often overlooked in terms of how administration occurs and when the 
taper of these therapies begins. Anecdotal findings suggest that prescribers continue to prescribe 
medications with intended harm reduction approaches instead of focusing on abstinence. This 
study focuses on the history of opioid prescription, addiction, and medical information regarding 
medication therapy, harm reduction, and the deliverance of why persons administered MAT has 
been prescribed for an extended amount of time. This study focuses on who is primarily 
responsible for the length of MAT treatment. Interviews with persons previously or currently 
prescribed medication-assisted treatment will initiate personal experiences to conclude whether 
the client or physician controls MAT administration length. Recommendations of participants 
will be discussed regarding their opinions on the length of treatment. 
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Chapter I: Statement of Problem 
Opioid addiction is an epidemic that primarily affects the U.S. but is also gaining speed 
in other countries worldwide. The epidemic began with the illegal use of prescription level pain 
relievers (Koehl et al., 2019) but is also affected by illicit opiates without the initial prescription 
of an opiate. Continued use from desired intoxicating effects may lead to serious physical and 
psychological dependence. The number of people affected is continuously rising, as have the 
number of those seeking addiction treatment. In 2006, more than 30,000 people lost their lives 
lost to opioids and, out of all drug-related deaths, opioids are the leading killer (Genetics Home 
Reference, 2017). Over the last ten years, the number of opioid-related deaths increased 
significantly, totaling 50,000 deaths (Opiate Addiction, 2020). This number of overdoses 
increased by 30% from 2016 to 2017 alone (Collins, 2020), indicating these numbers are 
drastically increasing over time.  
In 2017, there was a significant increase in opioid-related deaths for 47,600 Americans; 
however, there was a slight decline in those deaths in 2018, totaling 46,802. The dependence 
problem stems from the over-prescription of pharmaceutical pain relievers that began in the 
1990s (Collins, 2020). Opioids were initially intended to treat chronic pain. However, the long-
term effects of repeated use and the risk of addiction increased as physicians continued to 
prescribe these medications. Over time, when a person's prescriptions ran out, withdrawals 
became more frequent. Since the dependence had already been established at this point, 
discovering an illicit form at a relatively low cost became the new method to treating the pain. 
Nearly 130 individuals die daily in the United States due to an opioid-related death 
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(NIDA, 2020). The costs for this crisis are estimated at eighty billion dollars a year for treatment 
in healthcare and judicial standings (NIDA, 2020).  
Medication-assisted therapy and counseling therapy can have the ability to discontinue 
opiate use significantly and overall decrease the number of overdoses that occur each year. This 
review examines research concerning opiate addiction and treatment methods of methadone and 
buprenorphine to discontinue illicit opiate use. In addition, this study addresses who is 
responsible for prescribed medications, whether it be the client in control or physician. This will 
gauge whether those prescribed the medication could complete treatment after a certain period of 
time successfully without relapsing. Research supports such medication's effectiveness, yet there 
is no evidence of why opioid users undergo treatment for an extensive amount of time. This 
review will include research from studies on how methadone and buprenorphine treatments are 
prescribed and other significant findings specific to the treatments' characteristics. Harm 
reduction will play a factor in the research, taking the role of the physicians' alternative approach 
when prescribing the medications. 
Koehl et al. 's (2019) treatment modality is known as abstinence-based programs, will be 
discussed. This treatment modality holds higher success rates for sobriety without medicated 
assisted therapy. Counseling therapies reduce the mental suffering of those with opioid use 
disorder, develop relapse prevention, and strengthen healthy coping skills. In contrast, 
medications-only approaches are found only to decrease the danger associated with 
withdrawals.   
This research aims to dive deeper into the opioid addiction crisis and educate on the 
impacts medicated therapies have on those prescribed through interviews of personal 
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experiences. This study will also explain who is in primary control of continued medicated 
treatment for opioid addiction. Continuation of medicated therapy questions whether opioid users 
are not ready to discontinue or simply abuse the medication-assisted therapy or whether the 
concern lies with the prescriber. However, it can be understood there are contradictory truths 
amongst all concerns.  
      This study employs a grounded theory approach. Asking a question to derive a hypothesis 
following analysis of the data. The question presented focuses on who is responsible for the 
continued prescription of medicated assisted therapy for those diagnosed with an opioid use 
disorder? This question is undecided between the client and the physician. Whether physicians 
may not begin to taper clients, persuading into a continuous prescription, or whether the 
continued treatment is solely up to the client. Contrarily, the physician may not have adequate 
knowledge on how to prescribe the medication, and Louie et al (2019) explains some physicians 
may not provide adequate services due to the difficulties treating that specific population, 
resulting in them being responsible. A final questioning factor is the monetary benefits 
physicians receive. As for the client, a recent study indicated that those who preferred methadone 
continue use to remain under the opioid's influence. In contrast, those who preferred 
buprenorphine wanted to discontinue their drug use altogether and stay abstinent (Bennett, 
2011). Lastly, clients may continue their medicated assisted therapy (MAT) prescription by not 
completely being ready to make a choice to become abstinent. 
To prevent the client from manipulating the assisted therapy programs, the physician 
must follow proper treatment guidelines to perform a full assessment. These guidelines provide 
knowledge on how to administer medicated assisted therapy and when it is safe to taper the 
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client. However, if a physician does not follow the strict protocol, the clients may abuse the 
medications. This may happen if the physician allows the client to remain on the medicine for an 
extensive amount of time. There is a blurred area of why a client is on their prescribed treatment 
for a long duration, between the responsibility of the client or the physician. Interviews 
conducted from the client's perspective can initiate a deeper understanding of why they believe 
whether they are responsible for continued treatment or if it is controlled by their physician. 
These interviews will discuss what the client personally recommends the duration of the 
medication. 
           This thesis hopes to develop a hypothesis to determine whether the user or the prescriber 
causes the presenting issue of continuous treatment and possible action steps to shorten the time 
spent on medicated treatment. Making available the firsthand experiences of users in treatment 
can develop other studies to help those who struggle with opioid addiction. It is ethically 
reasonable to obtain an insider's thoughts to understand the full effects of the treatment it has on 
those prescribed. Studying persons with real-life experience can provide an insight into the 
struggles associated with medicated treatment therapy and the cultivation of what needs to 
change for effective treatment to allow for abstinence without medications. 
It is essential to understand the client’s goals when entering treatment. Some may want to 
continue using, as stated for those who prefer methadone, but some may want to completely 
diminish their addiction and live a life free from addiction and medications. With hopes that 
most people want to battle their addiction and establish abstinence, this study will focus on the 





Antagonist. Does not produce a similar effect as agonists. It can obstruct the opioid from 
reaching the receptor that allows for euphoric effects. 
Buprenorphine. Partial agonists are prescribed to those with opioid dependence. This 
form of treatment is placed under the tongue in a sublingual tablet at low dosage rates. 
Full Agonist. Fabricates maximum potential within the brain when activated. Obtains the 
same chemistry of partial agonist, however at full potential.  
Half-life. Duration of time before the drug removes from the bloodstream. 
Harm Reduction: The concept of understanding drug use is apparent, and some are not 
able to stop. Allows for death reduction by keeping people alive by still obtaining the ability to 
use but in a safer manner (E.g., safe/clean needle exchange to prevent HIV, safe doses to avoid 
overdosing). 
Length of time in treatment. The duration client is active in treatment with medicated 
assisted therapy.  
Medicated Assisted Treatment (MAT). Use of medications and therapy for the 
treatment of opioid use disorder.  
Methadone. Full agonist that acquires longer-lasting effects than regular opioids to aid in 
the treatment for opioid addiction.  
Mu-opioid receptor. Receptors located in the amygdala release dopamine, reinforcing 
pleasure, and rewards systems within the brain.    
Opioid/Opiate. A substance that produces a euphoric like experience in a user, nearly for  
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alleviating pain. Found in prescription medications (oxycodone, codeine, morphine) or 
illicit versions (heroin). 
Opioid Use Disorder. Self-administering of an opiate that no longer serves for medicinal 
reasons such as injury. The disorder characterizes obsessive thoughts and actions towards using 
an illicit drug. Users have elevated tolerance and dosage to obtain a euphoric experience. 
Withdrawals are prevalent if the user does not continue the administration of the drug. 
Partial Agonist. Attaches to receptors within the brain to partially activate the opioid 
receptors.  
Pharmacotherapy. The treatment of a disease through the administration of drugs.  
 Taper. The gradual decrease in methadone or buprenorphine. 
*Definitions cited from Substance Abuse and Mental Health Services Administration (2018) and American 
Psychiatric Association DSM V (2013).   
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Chapter II: Background 
Opioids began with the intent to aid in pain management, post-surgery, or any intense 
medical procedure. Common prescription opioids include morphine, hydromorphone, codeine, 
oxycodone, and hydrocodone. Street opioids include heroin and fentanyl (Strum, 2020). Most 
opiate addiction starts when a person sees a physician who prescribes prescription medication to 
aid in chronic pain. Jones and McCance-Katz (2018) state in their research regarding the opioid 
history and strategies for pain management that prescribing doctors are fully aware of the issue at 
hand and are continuing to be an active member in the crisis. The issue is, there is no evidence 
for long-term treatment to aid in chronic pain to this date. The problem of chronic distress causes 
conflict from one prescriber to another. Some may have good intentions to help the population, 
whereas some physicians lack this quality, yet some may have those positive intentions yet make 
wrong choices. Physicians that did not use opioids for treatment were shamed and told they were 
unethical and "inhumane" for not prescribing pain medications for those in need. This led to 
many more physicians prescribing opioids to diminish the stigma attached to medical doctors 
(Jones et al., 2018). However, negative stigmas were still found to be attached to those 
associated with the disapproval of continuous prescriptions. Prescribing one an opioid for pain 
following a discontinue in their medication may lead them to the illicit forms (Lahey, 2016), 
causing them to become even more addicted.  
The presenting issue that remains is that many people may become addicted if they 
continue prescription use and gradually turn towards illicit ones such as heroin when these 
prescriptions are discontinued and when the onset of withdrawal is experienced. As mentioned 
previously, illegal use is exacerbated by the low cost and the fact that these drugs are readily 
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available on the streets (Opiate Addiction, 2020). Other factors associated with opiate addiction 
relate to prior drug use, certain personality traits, and undergoing traumatic upbringing (Genetics 
Home Reference, 2017; Somer, 2005). As these types of drugs are continued over long periods 
of time, changes in brain chemistry occur, which leads to psychological and physical dependence 
that then creates unwanted withdrawals when abruptly discontinued.  
           When people become addicted to opiates, many changes occur within their brains. Upon 
entering the bloodstream, the drug mimics the nervous system's receptors on our learned 
behaviors, the reward center, and pain receptors (Genetics Home Reference, 2017). The primary 
receptor the opiate attaches to is the mu-opioid receptor. Upon administration, it mimics this 
receptor, opening voltage-gated channels in the synaptic membrane to release dopamine. When it 
releases dopamine, it releases an extensive amount, acting as a reinforcer (Mistry et al., 2014). 
This reinforcer establishes a connection between the substance and the brain for needed repeated 
use to develop that feeling of euphoria. Upon first use, the user may only experience the highest 
intensity of that feeling. The only way to feel that close of euphoria is by using the drug again. 
With repeated use, the brain ceases to create more dopamine (Opiate Addiction, 2020) creating a 
cycle of continued use to experience pleasure and avoid pain. Since the brain now has difficulty 
producing a healthy dopamine level, it makes the dependence often visible within users and 
addicts, such as pale skin, weight loss, needle marks, and isolation. The drug then alters the 
brain's neuroplasticity (Mistry et al., 2014). The brain relies on that drug to provide it with that 
external dopamine release, which then changes the brain cells (Opiate Addiction, 2020). Without 




Some people are more vulnerable to addiction than others. For those who are more 
susceptible, after a few consecutive repeated uses, addiction takes over, leaving one with 
increased tolerance and dependence (Opiate Addiction, 2020). These drugs have an intense and 
powerful effect on the brain, as stated, making it difficult not to use them (Genetics Home 
Reference, 2017). Opioid addiction is fast due to the strength and changes that occur rapidly 
within the brain. Once the habit becomes established, it is a long road to recovery. The user may 
quit cold turkey, but typically they will gradually taper off the drug; otherwise, they will 
experience withdrawals that can be unbearable. Withdrawals can be painful, including nausea, 
depressed mood, insomnia, vomiting, cold sweats, and difficulty eating (Mistry et al., 2014). 
Often repeated relapse is seen due to the powerful cravings, painful withdrawals, lack of healthy 
coping skills, and altered brain plasticity. However, an alternative method for treating those who 
have acquired dependence on these substances with extreme withdrawal symptoms.  
The most commonly prescribed medicated therapies in a clinic are methadone and 
buprenorphine. Although these medications are the most commonly prescribed, research found 
that medicated assisted therapy is deemed "underutilized" (Jones, McCance-Katz, 2018), due to 
the lack of education on how to prescribe the medications properly. Besides medications, 
clinicians often recommend that clients participate in counseling therapy to establish skills 
specific to relapse and understand triggers that initiate the relapse. Jones and McCance-Katz 
(2018) indicate an effort in educational training for prescribers to require a therapeutic setting for 
treatment to work effectively. However, since there is minimal knowledge acquired, this causes a 
decrease in the agreement to prescribe the medications.  
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Before administering medicated therapy, the clinician needs to understand where the 
client is at with withdrawal experiences. When determining the severity of withdrawal, clients 
differ from one another on physical effects and intensity. One may experience detrimental and 
unbearable withdrawals, whereas one may believe they are manageable. To effectively determine 
how severe the withdrawals are, the clinician will present the client with a Clinical Opiate 
Withdrawal Scale, formally known as "COWS" (Koehl et al., 2019). This assessment is used 
before medicating to determine how much medication is necessary for the initial administration 
dose and continued treatment. 
Wesson and Ling (2003), the COWS founding creators, inform readers of its 
implications. Dr. Wesson developed the scale to distinguish withdrawal from intoxication 
(Tompkins et al., 2009). Some physical symptoms may present as either under the opiate's 
influence or as withdrawals from the lack of opiates. This scale asks questions based on pulse 
rate, gastrointestinal symptoms, if they experience any tremors, sweating, restlessness, body 
aches, runny nose or eyes, anxiousness or irritability, and dilation of the pupils (Wesson & Ling, 
2003). Tompkins et al. (2009) performed a validity study to determine whether the scale was 
reliable and valid when cultivating results from mild to severe withdrawals. As this scale helps 
determine the severity of physical dependence established in the user, it was consistent with 
measuring and identifying the symptoms across time by following the distress and determination 
of whether the symptoms were increasing or decreasing with the continuation and 
discontinuation of use. The study found that the scale was highly accurate when administered to 
opiate users.  
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In addition to withdrawal severity, specific medication doses are determined and 
administered to achieve stability – meaning not sedated nor experiencing withdrawals. To 
determine whether a client has achieved stability, the clinician must observe whether the client 
has officially met a balance in their life. The client must report a clean urine analysis (UA) to 
ensure they are no longer using illicit opioids. The clean urine must accompany no present 
cravings in addition to a decrease in withdrawal symptoms, physically and mentally (SAMHSA, 
2018). Along with medicated therapy, it is recommended that clients participate in group and 
individual therapy sessions that implement psychosocial counseling, relapse prevention, coping 
skills, and potential trigger strategies to aid in a successful recovery (Jones et al., 2018). 
Medications alone will not cure the addiction. However, they will aid in the physical discomfort 
of withdrawals that many are reinforced to avoid by continuing using. 
Within the medical field, practitioners treat medical concerns through the concept of 
harm reduction. Harm reduction can often be viewed as an approach to establish a healthy 
balance in the person's life without causing harm (Kalk, 2018). Regarding opioid use disorder, 
this may include allowing the person to continue using at a safe needle exchange program that 
promotes healthy use if they choose to use it. Clients who participate in harm reduction may find 
themselves utilizing services available to them. These services include safe needle exchanges, 
MAT for clean, uncut drugs, and promote encouragement of progress towards abstinence 
(Williams, 2019). Since drug use will always be prevalent, the harm reduction approach, often 
used for other medical illnesses, began to help decrease overdose rates associated with those who 
still want to use opiates. 
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Harm reduction approaches for opioid use disorder are applied to decrease deaths and 
save people from overdosing. Medication therapy was introduced under this approach as a form 
of alternative to aid in treating opioid use disorder for those who want to continue use. The 
increase of medicated assisted therapy allows opioid users to medicate safely, including clean 
needles to avoid the spread of HIV and Hepatitis C, proper dosage to prevent overdose, and 
maintain withdrawals (Collins, 2020). With this, a significant decline in illicit opioid use and 
risky behaviors associated with the user is reported (SAMHSA, 2018; Livingston et al., 2017).  
However, it has been proven that opioid seekers tend to use the system to acquire a 
cheap, pure high to avoid withdrawal symptoms. These people are aware of the low cost of 
medications, easy access, and additional doses guaranteed upon beginning this type of treatment. 
Bennett (2011) states, as the heroin price increases on the streets, the quality reduces. In some 
areas, the high price keeps the drugs from being readily available, increasing the addict's chance 
of experiencing painful withdrawals. Medicated assisted therapies available for opioid users are 
becoming readily available due to government funding and providing a safer alternative for a 
constant clean high. The drug quality of these therapies is approximately 98-99%. With that 
information, this means the user, if seeking sedation can remain sedated as pleased without the 
risk of withdrawal and at a low cost. However, some may not seek the sedation yet remain 
vulnerable to becoming sedated when administered. 
As this approach can benefit those who want to continue use, there are pitfalls associated 
with clinics that practice harm reduction. Clinics are often hot areas for dealers and users to 
locate and use (Williams, 2019). Generating an area of previous users, this can cause conflict and 
triggers for those aiming for abstinence. From a prescriber's perspective, it is often noticed that 
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the client's goals are disregarded (Kalk, 2018). If one has the goal of abstinence, but the 
prescriber practices harm reduction, the client may never see life without a dependence. 
However, those clients who often push for abstinence at an early stage are often seen as most 
vulnerable to relapse. The prescriber must keep reanalyzing the client to ensure they understand 
the client's goals since abstinence and harm reduction are viewed at opposite sides of recovery. 
Nevertheless, those who do not receive medicated treatment or counseling therapy maintain their 
likelihood of remaining addicted. 
Anecdotal evidence mentions that the addict goes from paying a dealer to paying 
pharmacies, yet their addiction does not subside. The addiction is then viewed as being replaced 
by a pharmaceutical and now not allowing for abstinence from overall opioid use. Bennett 
(2011) states that instead of healing the addiction, medicated therapy continues the dependency. 
Aside from harm reduction, this notion is yet a significant concern whether the physician is 
responsible. Is the physician keeping a client on MAT for monetary gain? 
Pharmaceutical companies benefit heavily from the number of medications administered 
to the community (Jones & McCance-Katz, 2018). This notion questions whether the intent to 
diminish opioid use is to transfer users from illicit form to licit instead of the goal of abstinence. 
Livingston et al. (2018) claim within their qualitative study that with an increase in kickbacks to 
physicians who prescribe opioids, they begin to provide non-effective services to their clients. 
Koehl et al. (2019) discussed misapprehension regarding prescribing and an absence of 





Pharmacotherapy for Opioid Use Disorder 
 The following section discusses the history of MAT and how methadone and 
buprenorphine work physically and mentally as an opioid treatment therapy. Also, research will 
be reviewed regarding these medications' outcomes to understand the benefits of their use 
further.  
Methadone 
 Treatment may be essential for those who have addiction problems, especially those who 
become dependent, physically and mentally on a substance. Scientists and doctors have teamed 
up to create a medicated-assisted treatment to limit drug use with tapering methods. Methadone 
was the first "long-term treatment" drug to aid in opioid addiction, founded in 1965 (Levran et 
al., 2012; Ali et al., 2017; SAMHSA, 2018). This medication is known for its long-term 
commitment and viewed as having a "ball and chain" effect, meaning that it limits one's freedom 
to live a life free from the medication (Livingston et al., 2017). Bennet (2017) stated, 
"methadone maintenance could serve as an indefinite "holding device" for those unable to give 
up opiates but would be willing to be maintained on methadone and reduce illegal use of drugs" 
(p. 133). Thus, the person would still be connected to a substance, thus supporting the notion of a 
ball and chain effect. 
Methadone is a mu-opioid receptor full agonist, meaning it causes the same effect as 
opioids when consumed. Methadone is an artificial opioid administered to discontinue illicit 
opioid use and decrease cravings and withdrawal symptoms (Levran et al., 2012; Kayman et al., 
2006; SAMHSA, 2018). During treatment with proper dosing, this substitute supports the body 
with withdrawal prevention and helps return the brain to homeostasis, allowing the user to 
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discontinue illicit opiate use (White, 2012). With each week of prescribed treatment, the user 
slowly weans off the illegal drug and continues to use methadone. Eventually, this process is 
followed by a progressive decrease in methadone consumption, known as a taper.  
The half-life of methadone, dependent on users, averages 24 hours, with eight being 
minimal and 59 being the most extended to be reported. Peak effects were noted between hours 2 
and 4 (Koehl et al., 2019). However, upon initial dose, those prescribed do not experience the 
full effect of the drugs until approximately day four. Prescribers found no maximum effect of the 
prescription as doses are increased – allowing for increased sedation with increased amounts. 
Like all medications, methadone has potential risks and side effects associated with use. The 
most detrimental risk is developing physical dependence from long-term use. Internal threats 
may include a higher chance of constipation, respiratory depression, arrhythmia, hypoglycemia, 
and hypotension (Koehl et al., 2019). 
According to the Substance Abuse and Mental Health Services Administration (2018) 
and Koehl et al. (2019), there are established guidelines in proper administering methadone. The 
initial dose of 5-10mg should begin slowly with a gradual increase every three to four days. 
Once the client has reached stability between sedation and withdrawals, the clinician continues 
administration, lengthening the duration between dosing to expand the time unaccompanied by 
cravings and withdrawals. Stable doses are typically an average of 60mg. This level of dosing 
has the best retention rate amongst users. Clinicians may administer higher doses to 
approximately 120mg, dependent on withdrawal and addiction severity. Once the client reaches 
consistent stability, the taper is then initiated, beginning at a 5-10mg decrease until a low dose is 
achieved. If this is successful, they may switch to BUP to allow for a smoother transition to be 
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completely off medications and follow a successful recovery. If a client chooses to withdraw 
from medication therapy without taper, the chances of relapse with potential overdose and death 
increase significantly to approximately 90% (Velander, 2018). Symptoms of withdrawal and 
cravings are still present, but the tolerance established before MAT decreased. Some are not 
aware of the significant decrease in tolerance and if they relapse, they may overdose causing 
potential death. However, those who do not initiate a taper and continue long-term use may be at 
risk of developing a physical dependence on methadone. 
Studies have found that the higher the dosage of methadone, the more substantial the 
decrease in illicit drug use (Kayman et al., 2006). According to Ali et al. (2017), when 
comparing methadone to heroin, it is not as damaging. However, there are no exact guidelines 
for how long the user should be on methadone (Kayman et al., 2006). Since there are no 
guidelines for the length of treatment, the focus of this study helps determine who is responsible 
for the continued MAT.  Issues have been known to arise when replacing illicit use with 
pharmaceutical dependence, questioning why there is no exact length of treatment. The 
misunderstanding is associated with not completely knowing when a client is stable since 
methadone produces sedating effects. According to Bennet (2011), methadone should only be 
prescribed to patients when they have already obtained a physical dependence on an opiate. If 
physical dependence is not prevalent within a patient's life, prescribing methadone may cause 
more addiction issues.   
Aside from the pharmaceutical aspects, methadone maintenance therapy strongly 
suggests counseling support to avoid replacing one addiction with the other. Meaning, when 
participating in this type of treatment, the user cannot only take methadone to diminish the 
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dependence; they should participate in counseling to see significant results firsthand. Those who 
withdraw from counseling therapy are increasingly vulnerable to relapsing (Schwartz et al., 
2016).      
Many stigmas have developed over time since the introduction of methadone half a 
century ago. According to White (2012), people believe that a user has not begun their recovery 
when using methadone but, instead believes that they start their recovery once they are off the 
methadone. These stigmas have caused extreme views and opinions regarding the treatment 
therapy. McElrath and Joseph (2017) also believe that it "reinforces" drug use rather than 
understanding that methadone is a part of the treatment and recovery process, which is then 
viewed as taking the place of an illicit addiction to a pharmaceutical addiction. (Louie et al., 
2019).  To conclude, there are negatives and positives associated with methadone maintenance. 
Some are pro methadone, whereas some are against the prescribed medication (Bennet, 2011). 
With scientists continuously growing research and aims to avoid stigmas, the following 
section will discuss how buprenorphine was introduced as an alternative and less harmful agent 
to treat opioid use disorder. 
Buprenorphine 
 More recently, doctors have developed an alternative method for opioid addiction called 
buprenorphine (BUP), or Subutex. This drug, introduced in 2001, is similar to methadone. This 
medication therapy is highly suggested for people who have opioid use disorder. The pitfall is 
that it is only available in urban areas. People with this disorder may lack available treatment in 
rural areas may come into conflict with a need to treat their addiction (Koehl et al., 2019). Unlike 
methadone, BUP is a mixed mu-opioid receptor partial agonist, meaning it only provides the 
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brain with partial intoxication. (Burns et al., 2015; Milne et al., 2009). When absorbed, BUP 
vigorously attaches to the opioid receptor to avoid other opioid bindings (SAMHSA, 2018). This 
drug does not allow the person prescribed to use other opiates while taking this medication; they 
will not experience effects simultaneously.  
Buprenorphine has a "ceiling effect" with maximum doses, establishing security for a 
safer boundary when administered. It provides no euphoric effect, unlike the alternative, 
methadone (Koehl et al., 2019). The purpose of BUP is to treat and detoxify opioid addicts from 
the illicit drug they used and provide them with stability from withdrawals and dependence 
without sedation (Louie et al., 2019). However, this medication can develop a physical 
dependence on the user with long-term use. If discontinued abruptly, those prescribed may 
experience withdrawal, which again supports why a taper is highly suggested (SAMHSA, 2018). 
Introduced in 2006, naloxone (NAL), a mu-opioid antagonist, has been combined with 
BUP and was popularized for its effectiveness in opioid replacement therapy (Burns et al., 2014). 
BUP/NAL, formally known as suboxone, is administered as a sublingual tablet, coming in two 
doses. BUP administration starts at 8mg and NAL at 2mg. Once the stability is established, an 
additional prescription at a slightly lower dose creates a taper in the prescription with BUP at 
2mg and the NAL at 0.5mg (Milne et al., 2009). A significant factor of this medication is that the 
half-life is around 37 hours, with a 24 to 69-hour average, disconnecting at a slower rate versus 
methadone's half-life of roughly 24 hours (Sansone & Sansone, 2015). Longer half-lives allow 
for less dosing and a mental disconnect from continued dosing, allowing for significantly lower 
rates of illicit drug use due to the higher duration of the half-life and inability to experience the 
other drugs’ effects. 
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The Substance Abuse and Mental Health Services Administration publishes guidelines on 
how to administer BUP in addition to methadone. Upon initial prescription, the first dose is 
prescribed at 2-4mg with two-hour supervision of the patients' response to the medication. The 
clinician may administer an additional amount if the patient is still experiencing withdrawal. The 
user may experience withdrawals for up to twelve hours. Upon beginning the medicated 
treatment, BUP is administered on a Monday, Wednesday, and Friday basis. Extended time is 
due to the extended half-life of the drug. Like methadone, proper dosing is achieved when the 
drug provides the patient with stability from craving and withdrawals without being sedated. 
Once the patient has acquired a stable balance between decreased withdrawals and 
craving, the clinician actively begins the taper. The Substance Abuse and Mental Health Services 
Administration (2018) implies that the taper starts by reducing the dose to 5mg with an extended 
time between administering an additional amount. It suggests significant results are established 
at a maximum dose of 30mg, where the taper begins. A downfall to starting the taper is that it is 
solely up to the client. Meaning that even though they are stable, they may not want to begin the 
taper. To avoid this, the clinician should educate the patient and encourage them to start their 
taper once stability is achieved. 
For a clinician to prescribe BUP, they must first receive a waiver before providing 
services. Eligibility to obtain the release is through the Substance Abuse and Mental Health 
Services Administration (SAMHSA). The administration, as of 2018, grants physicians the 
authority to prescribe up to 275 patients BUP. However, those who obtain a waiver are reluctant 
to prescribe due to their attitudes regarding the population (Louie et al., 2019). This belief may 
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be due to the physicians’ lack of education and their own opinions and biases. Those who lack 
the knowledge may pose a barrier in their treatment approach (Koehl et al., 2019). 
           Recent studies from Burns et al. (2014) and McElrath and Joseph (2017) have found that 
BUP has positive effects for those who willingly want to discontinue opiate use. The willingness 
could be associated with the significantly lower doses administered, concluding that this drug 
may be a better option for those who do not want to consume many treatment dosages (Burns et 
al., 2014). McElrath and Joseph (2017) state that users will experience fewer depression 
symptoms in a single dose. Users report they are also associated with a lower risk of illicit drug 
use and side effects. Reports also note that participants found it easier to engage in treatment 
when not forced and the opportunity to openly attend counseling treatment, which then leads to 
higher attendance rates. Other studies report that buprenorphine increases their overall quality of 
life. Mitchell et al. (2015) studied the four major domains of life on buprenorphine effects – 
social, environmental, psychological, and physical. He found a statistically significant increase in 
each domain when participating in this type of treatment. These positive attributes leave people 
feeling more comfortable when seeking out treatment rather than being stigmatized. This study, 
however, did not include at what time length clients reported a higher quality of life. 
           Much like all pharmaceuticals, there were some adverse effects found with the use of 
buprenorphine. Difficulty breathing and the likelihood of overdosing are uncommon; however, it 
is experienced with other opioid and IV use (Koehl et al., 2019). They also discovered that when 
undergoing treatment with other drugs, the medicated treatment can cause sedation within the 
patient. According to Burnes et al. (2014), the recovery rates for those undergoing this treatment 
are lower due to their first experience's unpleasantness. This could correlate with the 
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significantly low dosage administered. Users typically use large amounts of illicit drugs every 
day. When decreased drastically to a lower dose, this can cause uncomfortable feelings—
withdrawal symptoms such as nausea and vomiting. Studies have shown, indeed lower retention 
rates in BUP due to the patient not experiencing intoxication as found when using methadone 
(Bishop et al., 2018). 
Oftentimes, users undergo both types of treatment. When under the influence of 
methadone, they experience similar feelings as when using the illicit form. However, when using 
buprenorphine, they typically do not have the same physical and mental experience when using 
methadone or illegal forms. The following section will discuss research conducted on MAT's 
effectiveness, with highlighting the time attributed to being on MAT. 
Effectiveness of MAT 
When focusing on methadone, a study found that those who do not want to abstain from 
opiate use prefer methadone treatment, primarily due to the intoxicating experience (Bishop et 
al., 2018). A second study to solidify those findings conducted by Burnes et al. (2014) 
discovered that those who initially started on buprenorphine for treatment had transferred to 
methadone more often than those on methadone had transferred to BUP. This statistic found that 
the doses are smaller with BUP, and the euphoria experienced was not as powerful as with 
methadone due to the withdrawals from the initial taper. The Substance Abuse and Mental 
Health Services Administration (2018) also verifies that switching from BUP to methadone is 
significantly more remarkable due to the desire to avoid withdrawals. As stated previously, BUP 
does not provide a user with the sedating intensity experienced from methadone or the drug of 
choice. When interpreting the results of those who switched from BUP to methadone, the 
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euphoric feeling was not equivalent to the illicit experience. This study, however, did not 
mention how long a person had prescribed the medications or what time frame they switched 
between the medicines, or when the euphoric feeling was established.  
From a BUP perspective, Milne et al. (2009) deemed this treatment safer to use than 
methadone. The side effects of dependence, nausea, and vomiting are significantly lower with 
BUP due to the lowered dosages administered. Bishop, Gilmour, and Deering (2018) found that 
it was also more comfortable to withdraw after treatment was complete than when using the 
methadone treatment. According to Hser et al. (2013), those who pursued BUP treatment had a 
much more positive experience than those who chose the methadone treatment. However, the 
study conducted by Blum et al. (2017) found that the success rate amongst the two is similar. 
Nevertheless, both medications show improvement with a decrease in illicit drug use by the 
addicts undergoing treatment. Granted the findings of success rates for BUP, there was still no 
valued time frame of how long these participants were prescribed the medication to achieve 
successful withdrawal and report positive feedback.  
When comparing studies conducted on each treatment drug, methadone had a better 
retention rate than buprenorphine. Methadone was the preferred treatment method due to the user 
experiencing sedating effects. The limitation of this conclusion is specific to the dosage given to 
the patient. Methadone has a significantly higher dose than buprenorphine, making the retention 
rates higher for that drug. SAMHSA (2018) found that those prescribed methadone stay with 
treatment longer than those prescribed BUP. The reason being it is harder to taper off MET. It is 
questioned whether testing is performed to determine whether methadone doses can be 
equivalent to buprenorphine doses: either lower or higher. Although both substances deem high 
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retention rates from illicit opioid use, there was no provided therapeutic time frame from these 
results. 
In addition to retention rates, attention is also focused on the dosage amounts. When 
administered either drug, there was a significant difference in how much of the dosage one 
received. The lowest amount generally delivered for methadone is 60mg. One study showed an 
80% retention rate when given that specific amount. When given the highest dose of 120mg, the 
retention rate increased to 91%. As for buprenorphine, Hser et al. (2013) claimed that BUP's 
highest retention rate was only 60% on its highest dose of 32mg. Those numbers reflect the 
findings of those undergoing methadone treatment having 50% better chances of staying in 
treatment than BUP. This study implies that if treatment facilities increased the dose of BUP, 
perhaps to that of methadone, would retention rates increase? Although the amounts are studied 
heavily, there was no significance associated with how long they are administered to establish 
those retention rates.     
           While studies have shown that methadone has better retention rates, buprenorphine has a 
higher potential for true success. The quality of BUP administered is lower than that of 
methadone. These studies also conclude that there is a potential to be entirely off both illicit and 
treatment drugs when using buprenorphine. Methadone, however, does have the potential for 
aiding in the termination of illegal opioid use but is limited to complete termination of the 
medication. Koehl et al. (2018) suggest that BUP is preferred over methadone because of its 
adaptability. Allowing the client to remain in a stable state without withdrawals and sedation. 
There is also a preference for BUP due to the significantly low side effects experienced when 
undergoing treatment compared to methadone. However, the study states there is no evidence on 
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which drug deems to be superior to the other. Overall, both drugs show a significant contribution 
to overcoming opioid addiction. Again, granted research has found MAT effective to discontinue 
illicit use; there was still no duration for how long these participants were prescribed to establish 
the discontinuation of illegal use and terminate the medication.  
According to the Substance Abuse and Mental Health Services Administration (2018), 
when prescribing methadone or buprenorphine, the longer time spent prescribed MAT, the 
higher the success rates of discontinuing illicit use. Before continuing long term, the physician 
must consider the needs and goals of the client. In addition to MAT's continuation, a research 
study conducted on MAT mortality found an average time length of those prescribed MET and 
BUP. Those prescribed methadone therapies were averaged 363 days and 173 days for 
buprenorphine (Hickman et al., 2018). This study indicated that the average time for those to 
establish low morality levels was around the year and half-year mark. This information is 
essential to note that there are noticeable changes within the client around those milestones and 
perhaps consider beginning the taper at the point. However, it did not mention whether the length 
of time was therapeutic and did not include any additional information regarding time spent in 
treatment. 
To conclude, there is a significant potential associated with medicated assisted treatment 
to deplete opioid addiction. However, it is essential to note that psychotherapy should be 
encouraged while engaging in medicated assisted treatment to provide optimal outcomes. The 
lack of focus with each medicated assisted treatment is when these participants have been 
prescribed the medication is, for how long they were prescribed when effectiveness is 
established, and if they have enrolled in psychotherapy. Indeed, the results are positive and have 
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been proven to increase life satisfaction compared to what they may have been before the MAT; 
it is important to focus on the time frame for therapeutic effectiveness. 
As mentioned, this study aims to understand why opioid users are undergoing treatment 
for an extensive time when there are proper guidelines to taper a client from the medicated 
treatment. The Substance Abuse and Mental Health Services Administration (2018) provides 
physicians with the understanding and knowledge on how to properly administer each of the 
medicated treatments for opioid use disorder and how to decrease the medication of a taper to the 
eventual discontinuation of opioid use ultimately. Treatment protocol discusses what doses are 
administered for each prescription, dependent on the client's physical dependence and sedation 
level upon administration, including where the dose amount should begin, how to increase the 
dose gradually, and where and when to stop growing. The increase remains until withdrawals are 
managed and sedation is no longer. Following the plateau of the rise comes the decrease, which 
is when the taper begins. The protocol ensures how to accurately understand when to decrease 
the prescription and address the withdrawal and sedation levels, yet the time frame of when these 
interventions of taper being initiated are not looked at enough. It questions whether there is a 
lack of knowledge and education in the prescriber on administering medication correctly or if the 




Chapter III: Methods 
 The research in this study implemented qualitative findings derived from interviews with 
people previously prescribed one of the medicated opioid use disorder treatments previously 
discussed. Interviews focused on life experiences and perspectives regarding the length of their 
prescribed treatment. Data collected was used to develop an in-depth insight into why those 
prescribed MAT had to undergo long-term treatment. Chapter IV will review the results and 
summary of the data as written and perceived by the researcher. 
The Institutional Review Board approved this study from Saint Cloud State University. 
Participants 
This study obtained five adult participants, one of whom had experience with prescribed 
methadone and four with buprenorphine. Participants were either currently taking these 
medications or have done so in the recent past. Some also had experience with both drugs. The 
participants were recruited from various Minnesota locations and volunteered to be a part of this 
study. There was no stipulation as to the dosage amount used for their treatment or length of 
treatment. Drug of choice documentation, how long they were actively addicted, what MAT they 
received, and if they received any counseling services while undergoing MAT was provided (see 
Table 2). Maximum doses prescribed are included to provide additional conclusions when 
comparing other information (see Table 3). It is believed that those characteristics place value on 
opinions and beliefs regarding treatment regimens. 
Participants asked to participate, engaged in a one-on-one interview with the researcher, 
and were encouraged to provide truthful content to establish factual findings in this study. Each 
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participant was provided the opportunity to withdraw or take a break from the interview if any 
discomfort was experienced. Referrals for treatment help were provided upon request.  
Design and Procedure 
 Based on a grounded theory approach, this study used an analysis-based design focusing 
on the time spent with medicated assisted therapy to examine treatment perceptions—the 
primary data will be qualitative, collected by semi-structured interviewing. Data were collected 
from participants through face-to-face interviews via Zoom. Open-ended baseline questions 
gathered information regarding the participant's treatment, experiences, and perceptions 
regarding treatment. Private and confidential interviews were established to ensure a willingness 
to provide the researcher with accurate information. Quantitative data were collected to establish 
a fundamental understanding ground of each participant and their experiences. Quantitative data 
includes dosage, length of medicated treatment, length of active addition, drug of choice, and 
prescribed medicated assisted therapy. 
Interviews lasted approximately one hour and were recorded for transcription purposes. 
All interviewees were required to complete a consent form before questioning. Interviews were 
then transcribed to form codes to analyze the collected data. Based on grounded theory, this 
approach will help formulate a hypothesis regarding the data collected from participants.  
Participants answered similar questions based on their treatment to examine different themes and 
categories. Additional probing was performed to gather additional information regarding their 
length of treatment. These findings were placed into similar and different groups based on 
relevant information. The primary focus is given to the thoughts and opinions regarding their 
treatment length. The researcher will question how they felt about receiving treatment for as long 
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as they did/are and their beliefs on whether they thought they were in control of their treatment 
or if the physician was. 
Measures 
Upon questioning, participants provided information on what treatment was prescribed. 
They answered how long they have been on MAT and which medication they received. This 
information placed them into groups to find the similarities and differences between the 
responses provided. Another question asked was regarding their dosage of treatment and the 
maximum dose received. After collecting characteristic information, participants were asked, 
“what goals did you have entering medicated treatment?” “Do you believe being on MAT for 
your duration was/is effective?” “Was the length of time a form of harm reduction?” Additional 
questions regarding the role of their physicians were asked to break the barrier between who is 
responsible. Opinions regarding counseling services were also gathered. Lastly, thoughts and 
opinions for an opioid-dependent to be prescribed MAT for a certain amount of time was 
provided. Answers were noted and further analyzed by coding. Those who have been in therapy 
a long time will be asked if they see themselves coming off the medicated treatment anytime 
soon. Since this study is founded on semi-structured questions, the questions will begin similarly. 
However, once probing begins, data will be collected with questions specific to the individual. 
Analysis  
Upon completing the interviews, data were transcribed and coded, which placed 
participants responses into thematic groups. Codes were also combined to create different 
categories and themes to compare treatment types. The information focused on the differences 
and similarities in the length of their treatment experience. 
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NVivo coding system was used to aid in transcription and coding for recursive themes. 
This program placed data collected into a node to develop several codes specific to the interview 
responses. This method helped the researcher organize and analyze the data to combine 
participant experiences for further conclusion. All codes were given functional definitions to 
describe each participant's experiences that were similar and dissimilar. Post coding, a review of 





Chapter IV: Results 
 This chapter details the results analyzed from interviews conducted on those prescribed 
methadone or buprenorphine for opioid use disorder. Characteristics of the participants will be 
discussed through tables, and the results through qualitative quotes and codes developed from 
NVivo. A collective summary of the results will be provided at the end of this chapter. To begin, 
Table 1 describes participant characteristics to develop an understanding of the demographics of 
each participant. Table 2 explains the percentages attributed with Table 1 in addition to 
information not provided in Table 1. Table 3 provides an explanation of the prescribed doses 
over what years. This information will be discussed at the end of the chapter. Table 4 indicates a 
percentage of participants deem responsible for their treatment for how long they have been 
prescribed the medication. Lastly, Table 5 indicates a representation of client perspectives on 
how long one should be maintained on MAT to recover from opioid use disorder. 
Characteristics of the Sample  
Table 1 
Participant Characteristics with MAT 
Participant  Age Length of 
Addiction 










1 28 6 years Suboxone 1 16mg 2020 Yes 
2 42 21 years Methadone 2 200mg 2012 Yes 
3 24 2 years Suboxone 3 16mg 2018 No 
4 36 13 years Suboxone 4 32mg 2012 No 








 Characteristic Percentages (n= 5) 
Characteristics N % 
Gender 
     Male 
     Female 
 
Age 
     20-25 years  
     26-30 years 
     31-36 years  
     36-40 years 
     41-45 years  
 
Drug of Choice 
     Heroin* 
     Pills* 
     Fentanyl 
 
Length of Addiction 
     0-5 years 
     6-10 years 
     11-15 years  
     16-20 years 
     21-25 years  
 
Medicated Assisted Therapy (MAT) 
     Suboxone 
     Methadone 
 
Length of MAT 
     0-1 year 
     2-3 years 
     4-5 years 
 
Received Counseling for OUD 
     Yes 















































































Participant Prescription Data  
Participant MAT Prescribed Dose Years Prescribed 
1 Suboxone 16mg  2020-present 
2 Methadone 200mg*  2012-2014 
3 Suboxone 16mg 2018-present 
4 Suboxone 32mg* 2012-2016 
5 Suboxone 24mg 2016-present 
*Suboxone recommended doses: <30mg 
*Methadone recommended doses: <120mg 
 
Tables 1 and 2 explain the characteristics viewed in this study to develop an 
understanding of each participant's background specific to their addiction, drug of choice, 
medicated treatment, length prescribed MAT, how long they were prescribed, and so on. This 
provided the researcher with information to refer to when comparing the data provided by each 
participant. The average length of treatment in the study was three years, with a participant 
prescribed for only one year, and one prescribed for five years.  
Of the 5 participants (two male, three female), 4 (80%) have been prescribed suboxone, 
and 1 (20%) prescribed methadone. Between ages 36 and 45, two of the participants have been 
prescribed over the recommended MAT doses and began treatment in 2012. The additional three 
participants, between 20 and 36, are currently prescribed within the recommended dose range 
and have initiated treatment within the past five years. Each participant reports obtaining 
different drug choices, two of which held pills to be their first addiction, followed by heroin. 
Two of the three participants received counseling for opioid use disorder, one of which reports 
not receiving supplementary services. The following three participants report receiving MAT 
without OUD counseling services. 
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As the study primarily focuses on time, data was analyzed on recursive themes regarding 
physician’s role and participant’s role in treatment to formulate observations on who is primarily 
taking more responsibility for the length of time in treatment. The main themes focused on 
include physician-related factors, participant-related factors, opinions, and recommendations for 
length of treatment. Refer to Table 4 for a visual representation of client perspectives on who 
they believe was in control of the length of their treatment.  
Physician-related factors  
Harm Reduction. During each interview, participants were educated on harm reduction 
strategies and why the medical field uses them to deal with medical concerns. Participants 2 and 
4 believed the MAT was not a form of harm reduction. Participant 4 stated, “There was no harm 
reduction being on methadone. Methadone for me was not a treatment; it was an addiction.” 
Both participants continued on MAT at higher than the recommended doses for their entire 
treatment. They also noted the withdrawals were significantly worse than coming off of their 
drug of choice alone. One participant suggested that why would this be a form of harm reduction 
if it is worse than illicit use? Participants 3 and 5 reported they believe their treatment is a form 
of harm reduction due to decreased going backward with their recovery, and their physicians do 
not want to see them fail. However, participant 3 questioned “why are the withdrawals worse 
then?” This question was asked due to trying to understand the concept of harm reduction and 
why it would be applied to treatment if there is more harm done once discontinuing the 
treatment. Participant 1 did not report on harm reduction due to early initiation of treatment and 
believe they control their treatment. 
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Monetary Motivation. A perception of the participants was that their treatment length 
may have been continued due to increased benefits for the physician. This recursive theme was 
held for 60% of participants that the physician is primarily responsible for continuing their 
treatment longer than necessary. Of course, it is not certain this is the sole reasoning, but it was 
mentioned enough to provide a section on the theme. Participant 4 mentioned that continuing 
treatment was “filling his (the physicians) pockets.” They then questioned, “I don’t see why you 
would maintain somebody for that long if there weren’t something behind it.” The other two 
participants suggested the reason they were prescribed for as long as they were/are having some 
affiliation with their physician receiving money for maintaining a prescription with them. 
Participant 2 strongly stated, “I never once was encouraged to get off the methadone therefore, I 
have thoughts on the idea that it may have something to do with money. There was no “harm 
reduction” from being on methadone.” There is an idea that physicians may be motivated by 
increased benefits for maintaining these medications, whether it be suboxone or methadone. 
Participants from each prescription group indicated some form of money motivator within their 
interview.  
Negative Perspectives. There were also additional negative themes associated with 
physician’s worth mentioning. Participants 2, 4, and 5 reported that their physicians never 
encouraged them to begin a taper and begin thinking about life outside of MAT. Participant 4 
reported persistence on beginning their taper every time they refilled their prescription but 
reported receiving a deny after each request. After asking to taper, a reported comment from a 
physician said, “if you want to lower your doses, do it on your own.” The lack of encouragement 
and direction was “offensive” according to participant 5. Participant 5 indicated their physician 
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continually “pushes” them to remain on MAT regardless of their goals. Participant 2 indicated 
they only saw their physician twice, which made addressing their treatment difficult. Each 
participant indicated negative experiences while working with their physician and their MAT.  
Participant-related factors 
Positive Choice. Positive perspectives were not included in the physician-related factors 
section due to the positives recorded were associated with the client’s ability to have a choice 
regarding their treatment. Two participants mentioned that their physician met them where they 
were at with their treatment. Participant 1 and 3 provided positive regards towards their 
physicians and how they approached their treatment management. Both implied their physicians 
were very supportive in their recovery and were meeting them where they are in their recovery. 
Participant 1 reported that their physician provided them with information regarding 
approximately how long they would be on their prescription. Whereas participant 3 reported their 
physician allowed continued treatment for as long as they needed to, to avoid relapsing. They 
both participant 1 and 3 reported that their physicians are there to help them through their 
recovery on their own terms. However, the concluding factor for both participants was that their 
treatment and length are solely up to them.  
Negative Choice. Two participants explained that they are partly held responsible for the 
continuation of their MAT. Interestingly, they both noted the withdrawals as a driving motivator 
for them to continue treatment. Similar to the thoughts of participant 4, both participants reported 
remaining on MAT due to withdrawals being significantly worse than the drug of choice (DOC). 
Both mentioned they were “scared” to begin a taper and discontinue due to experiences they 
previously encountered with withdrawals. Aside from being afraid of withdrawal experiences, 
42 
 
one participant stated they remained in treatment initially because they wanted to and enjoyed 
the euphoria associated with increasing doses and no desire to change. “I lied because I wanted 
more. They asked me if I was experiencing any withdrawal symptoms and I would say yes. I was 
never denied any dose increases.”  
Table 4 
Participant View: Who’s Responsible for Length of Treatment 
Responsible  Suboxone (n=4) Methadone (n=1) Total (n=5) 
Physician 25% 0% 20% 
Participant 50% 0% 40% 
Both Parties 25% 100% 40% 
Total 100% 100% 100% 
 
 Table 4 provides a percentage-based visualization regarding the belief of participants for 
who were most in control of their length of treatment. Although not directly stated in the 
interview, two participants made separate comments concerning a contradiction leading to an 
understanding that both parties were in control of the continued treatment. The participant 
prescribed suboxone noted that initially the physician was to hold them accountable due to 
continuously pushing them to remain on the prescription. However, they are afraid to discontinue 
their prescription due to the severity of withdrawals. This participant made known that the 
beginning of their treatment was dependent on the physician’s responsibility, resulting in them 
being in control due to a fear of withdrawals. This statement placed the participant in a category 
of both physician and participant responsible for the length of treatment. For the methadone 
participant, it was mentioned that upon initial months of treatment; they would like to have their 
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doses increased due to the enjoyment of remaining under the influence. Nevertheless, they stated 
the physician was motivated by money to maintain a prescription without physically speaking 
with the client. The money motivator was indicated as the prescription continued and the 
addiction became increasingly worse. This participant developed an understanding of the 
beginning of their treatment was in their control. However, as treatment continued and their 
addiction got worse, the perspective regarding who was responsible for their treatment changed 
roles. These comments placed both participants in a Both Parties category due to contradictory 
truths amongst the two. To conclude, it is essential to understand how parties are responsible for 
their prescription. 
Opinions and Recommendations 
 Despite the discussion about who is primarily in control, participants provided 
information regarding opinions and recommendations for time spent on medicated assisted 
therapy for opioid use disorder. This section will focus on participant treatment 
recommendations pertaining to the length of treatment and additional themes found throughout 
the data.  
 Opinions of Methadone. Due to only one participant being prescribed methadone, those 
prescribed suboxone were asked to provide any thoughts on the alternative treatment. Of the 
four, three mentioned that those prescribed it may receive euphoric highs while being prescribed. 
Interestingly noted, participant 4 commented on the euphoric highs attributed to prescription: 
I don’t understand why they think it’s effective or why it’s necessary. There are better 
ways to go about things. Harm reduction… I understand that, but then why do they have 
to bring people up so high, to bring them back down? It doesn’t make sense. 
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This participant commented on the full agonistic effects of methadone. Due to there being no 
ceiling effect, unlike suboxone, there is a much higher likelihood of experiencing complete 
sedation. The participant who was prescribed methadone indicated if having known the effects of 
methadone, they would have never begun treatment. Primarily due to the completed sedated life, 
they were living with methadone maintenance. This participant reports undergoing an “awful 
experience” with their prescription of methadone. The participants prescribed and not prescribed 
provided the researcher with negative feedback regarding methadone treatment.  
 Opinions of Suboxone. All four participants prescribed suboxone provided positive 
feedback regarding their experiences with their treatment. Each stated they were thankful for the 
opportunity to regain control of their life. However, the two participants prescribed over four 
years ended with negative comments. Positive feedback is as followed. Participant 3 states, “I 
don’t know if I would have stopped using (illicitly) honestly, and then I got on (suboxone) and 
was able to stop.” Each participant stated they were thankful for the opportunity and how far 
they have come with their recovery with the help of suboxone. Participant 1 reported suboxone 
was a “lifesaver” and believes it has helped them immensely. Other participants concluded it 
provides mental clarity with providing the ability to set future goals for themselves. These two 
participants' negative comments were related to the length of their prescription. Both participants 
reported wishing they would have begun their taper faster than continuing their prescription. 
Participants provided research with positive notions regarding suboxone, with conflicts between 
participants on how long they should be prescribed.  
 Recommended Time Length for MAT. Methadone and buprenorphine obtain different 
mechanisms of action and intensities of sedation level, so it is necessary to keep 
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recommendations for each medication separate. The participants prescribed methadone for two 
years and reports to those prescribed not to exceed a year on methadone with a maximum dose of 
60mg. This being explained by not allowing oneself to become sedated by the medication and 
avoid replacing their previous addiction with the new addiction of methadone. Additionally, this 
allocated time frame and the maximum dose may aid with the balance of not becoming sedated 
and managing the withdrawals for a short amount of time to taper off the medication eventually. 
 For the participants prescribed suboxone, there were different beliefs amongst the four 
participants. Two indicated that depending on where the person is at with their recovery, to 
recommend remaining on MAT for as long as necessary. This will ensure the high-risk person 
does not relapse leading to a higher risk of overdosing. Participant 3 states, “if you’re going to 
relapse and go back to using, I think you should probably just stay on it.” Of those two, the other 
participant mentioned only to be prescribed the medication for roughly a year and a half. The 
following two participants mentioned that people prescribed suboxone should get off as soon as 
possible. Indicating that once stability is achieved, one should discontinue their prescription. 
Participant 4 indicated that six months is “more than enough” for time allowed to get stable and 
lessen the chances of intense withdrawals following the taper. They believe the taper should 
begin at month three or four, resulting in an approximately six months of medicated treatment. 
Participant 5 estimated one to two years but again suggested getting off as soon as possible. This 
person reported blaming themselves for continuing treatment as long as they did and wished they 
would have been off in a year but felt pressured due to their physician continually doubting their 
recovery, as stated. Both participants strongly recommend tapering off MAT before the 
withdrawals get severe to where the person is afraid to come off. To conclude, from the reported 
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information, it was found that if one is able to abstain from using, to get off MAT as soon as 
possible. 
 For those who are currently prescribed MAT they were asked whether they view 
themselves beginning taper in the near future. Participant 5 mentioned in their interview that 
their physician denied their request for taper and was told to if they wish to taper, to begin on 
their own. The participant reported it was difficult for themselves to have a continued 
prescription at the same dose and not a tapered one, to begin to taper themselves. They indicated 
hopefully being able to begin a taper on their own soon. Participant 3, on the other hand, 
indicated they would continue their prescription due to their physician allowing them to request 
changes in their doses whenever they deem necessary. This participant reports requesting to 
lower on their own terms and increasing if they feel the low dose is not therapeutic. This 
information is important when considering their length of treatment and who is in primary 
control. Participant 3 continues with the notion that they are in control, whereas Participant 5 
finds it difficult to discontinue the help of their physician to initiate the taper for them upon each 
request.  
Table 5 
 Participant Recommended Time Length  
MAT (n=5) < 1 Year 1 - 2 Years As Needed  Total % 
Methadone (n=1) 0 1 0 20% 
Suboxone (n=4) 1 1 2 80% 




 Table 5 demonstrates the amount of time each participant recommended as necessary for 
time spent on medicated assisted treatment. As mentioned above, participants hold different 
beliefs regarding the length of treatment. Sixty percent of the participants believe one should be 
maintained on medications for a certain amount of time, in contrast, following 40% believe one 
should stay on for as long as they need to, depending on where they are at in their recovery. 
Those who believe in a certain time period is due to the hardship associated with increased 
withdrawal severity and decreased developed dependence from the illicit forms. The two who 
believe in extended treatment report that the longer the treatment, the chances of relapsing 
decrease.  
Psychoeducation. Participants were asked whether they received any counseling services 
or co-occurring education for opioid use disorder while receiving their medicated treatment. As 
noted in Table 2, only two participants received counseling for their addiction. One mentioned 
that while receiving their MAT, their counselor did not address their addiction and only spoke of 
minor occurrences within their life. They did not find those services beneficial to their addiction 
and were only recommended taper when the participant mentioned one. The other participant, 
included attending outpatient services while receiving MAT to strengthen their understanding of 
triggers and develop a relapse prevention plan. This participant reports positive experiences with 
both medication and counseling integrated with their recovery to battle their addiction. 
 The other three participants report never attending counseling services for opioid use 
disorder while being prescribed MAT. However, they each reported that counseling should be 
encouraged while receiving any opioid treatment medication. “This is how people could quit and 
be successful” quoted from participant 5. Healthy coping skills are needed to be developed to 
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build accountability and learn to work through addiction. Participant 4 stressed setting a new 
path for themselves (clients prescribed) and actually living a sober life, not just being sober, e.g., 
learning differently and forming new habits. Counseling services for those who struggle with 
mental health attributed to use were noted can be beneficial to tackle addiction. Individual and/or 
outpatient counseling services were predominant when asking participants about their thoughts 
regarding psychoeducation for opioid use disorder.  
Summary 
 A conclusion from the small sample of participants, it was found approximately equal 
responsibility of both the participant and physician regarding the time spent on medications for 
opioid use disorder. Two participants addressed that the length of their treatment was utterly 
dependent on their recovery stage. In contrast, another two believed the physician was strictly 
maintaining their prescription for monetary benefit with no regard to harm reduction. The fifth 
participant is what determined an equal balance between both contradicting sides. This 
participant believed they were in control due to the fear of withdrawals yet believes the physician 
has some monetary grounding force for the continuation of the prescription. Due to the sides 
obtaining equal beliefs, additional comparisons were noted to draw a further summary of the 
data.  
With a focus on who was in control, after thorough analyzing and comparing tables, a 
correlation was noticed between those with over ten years of addiction and ages over 30 (n=3), 
held negative perspectives that it was the physician’s responsibility for the amount of time they 
maintained the prescription. These same participants agreed on their ideal time of prescribed 
medicated treatment to be roughly one year. On the other hand, those with active addiction less 
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than ten years (n=2), stated it is solely up to them regarding how long they maintain their 
medication for recovery. The two groups of same participants were noticed to obtain similar 
characteristics of similar lengths in addiction and belief regarding role in continued treatment. 
Along with lengths of addiction, it was discovered that those in the same group of more 
prolonged addiction held more negative perspectives towards their physicians than those two 
were in the less than ten years of addiction group. Those participants reported positive feedback 
regarding their physician and how they approached their treatment prescription.  
 In addition to years of addiction, it was noticed that the participants prescribed in the year 
2012 (n=2), received over the recommended doses of MAT for their specific prescription. As 
mentioned in Chapter II regarding physician’s lack of education, those doses may have exceeded 
the recommended dose due to the lack of education. A correlation between the small sample of 
those two participants with their beliefs to who was responsible for the length of the treatment 
was anecdotally documented. Since methadone was synthesized in 1965 and suboxone in 2006, 
the amount of research across both medications varies. The participant prescribed in 2012 
worked with a doctor who had a maximum of six years of knowledge about the medication. This 
raises a concern about whether they were educated enough on the medication protocol for 
prescribing. Conversely, those who received MAT of suboxone at later dates (2018 to present), 
have a higher likelihood of obtaining a physician who is more educated on the medications and 
how to prescribe. These participants were noticed to receive appropriate doses for their 
treatment, in addition to holding the belief that they were either in control – or partly in control 
(Participant 5) for their prescription being continued. This participant began treatment in 2016, 
whereas the other two were at a much later date. 
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 Due to the small sample size, a relationship was found between the length of MAT and 
who was accountable for treatment with the suboxone participants (n=4). The methadone 
participant is not included in this relationship due to being the only participant recruited in the 
study. The participants who were maintained for four to five years stated it was their physician 
who was responsible. The other two participants, less than three years, believe they are in 
control. Along with this information, gender was noted to be affiliated with this relationship. The 
two participants who believed they were not in control of their time spent on MAT were males, 
and the two less than three years were females. To conclude, the participants with shorter MAT 
prescriptions stated they who were in control, whereas the one with a longer MAT prescription 
believes it was not. 
 Switching focus to those who received counseling services and was held accountable, 
there was no correlation. Only two members received services with one believing each was held 
accountable. The other three participants had similar findings. To conclude, there was no 
relationship between those receiving counseling services for OUD who believed it was their 
responsibility or their physicians. To establish a relationship between these two factors, more 




Chapter V: Discussion 
Hypothesis 
This research focuses on the factors of whom clients believe is responsible and in control 
of their treatment regimen for how long they maintain MAT prescription regarding their opioid 
use disorder. Due to the small sample size, the findings were not strong enough to produce a 
concrete conclusion. Questions developed as the researcher developed the hypothesis leading to 
future research topics and focus. First, it will discuss the length of addiction, followed by the 
developed hypothesis. A researcher's perspective is provided in addition to the study's 
limitations. 
           From a philosophical perspective, after concluding the results and understanding the 
characteristics of those who have maintained addiction for a long time, blaming and justifying 
are common factors for those who have struggled with addiction. These cognitive distortions are 
central thoughts to those affected. With that in mind, one can believe that those who obtained the 
more prolonged addiction may still obtain those negative thought patterns if they abided by them 
and have used them as a bias towards their physician. It is not intended to direct the conclusions 
of why those who believe the physician is responsible, but it was noteworthy that may include 
distorted thinking in some responses. Are these participants still affected by those negative 
thought processes? However, it will identify that this statement will not affect the discussion and 
conclusion. 
           Despite the multiple unanswered questions this study has developed, this study's 
concluding hypothesis is presented. The longer a person is prescribed MAT, the harder it is for 
them to taper off the medication and become non-dependent on opioids/opiates. While the study 
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included questions to the participants regarding psychoeducation and therapy services, it is 
highly encouraged to engage in therapy to help decrease the amount of time spent on medicated 
assisted therapy. This hypothesis was derived from all parts of the study dependent on harm 
reduction, length of treatment, and counseling services. 
           Focusing on the concept of harm reduction may play a role in why some may need 
extended MAT due to the severity of their addiction and withdrawal symptoms. A question 
raised in this area was, are physicians causing more harm to the client by not engaging in a 
taper? This then causes an increase in withdrawals if discontinued. It is thought that the longer 
the person is prescribed, harm reduction decreases for the client due to the increase in severity in 
experienced withdrawals upon completion of the medication. Two participants stated they are 
afraid to begin their taper and eventually discontinue their prescription due to the anxiety 
developed from a fear of experiencing withdrawals. Those same participants who did taper off 
medications stated in their interview, it was the worst experience for six weeks to six months, 
worse than what they had experienced previously from their initial drug of choice. Shortening 
their time spent on MAT may decrease their eventual withdrawals from discontinuation. It is 
thought, if a person actively attends co-occurring education for their addiction, they may develop 
an understanding of why physicians integrate this approach into their treatment. People typically 
do not want to be prescribed and tied to medication for the rest of their life. Educating people 
prescribed these medications should decrease the amount of time spent on MAT and allow for a 
non-medicated dependent life. 
           Psychotherapy is currently encouraged to clients prescribed MAT; however, it is not 
required. Concerns to lessen the time spent on MAT should require those prescribed to receive 
53 
 
counseling services simultaneously. As stated by the participants, counseling is suggested to 
build a new foundation to live by, such as healthier coping skills and relapse prevention. 
Psychotherapy required with MAT would increase the person's resiliency to avoid relapse, 
understand triggers, and develop coping skills to build a structured life without use. MAT would 
help those at the beginning of recovery manage the deathly withdrawals while learning the new 
skills concurrently. Psychotherapy and MAT used together could decrease the amount of time 
spent in treatment altogether.  
           As briefly mentioned, withdrawals are a concern for those prescribed MAT and whether 
to continue their prescription or "bite the bullet" and manage through them to become free from 
the ball and chain effect stated in Chapter II. This generated another question, should counseling 
services be required with a low dose MAT prescription followed by marked stability? 
Considering this question, maintaining a low-dose prescription may allow the client to remain 
stable, hoping to decrease the severity associated with the final step of discontinuing the 
medication. 
           A difficulty is noting whether the client is truly sedated and experiencing withdrawal 
when physicians administer the Clinical Opiate Withdrawal Scale (COWS) as mentioned in 
Chapter II, or whether they are lying. Clients may lie about withdrawal symptoms to increase 
their prescribed dose. This was seen in the participants prescribed methadone. They stated that at 
the beginning of their treatment; they lied to increase their dose. However, the physician did not 
question or further analyze whether the severity was as reported. Not further assessing could be 
associated with the lack of education previous studies implied regarding physicians’ knowledge. 
As the medical field grows, it is hoped that it can develop a way to detect lying and false 
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information provided on the COWS to avoid increasing their dose when unnecessary. These 
lower doses may also make it easier for the client to decrease their time spent on prescribed 
treatment and decrease withdrawals' severity. Finally, the more educated the physician is on 
MAT, the more helpful they may be prescribing the medications, allowing for more direction on 
individualized treatment plans and educating the client.   
Conclusion 
From a researcher's perspective, both participants and physicians are held accountable for 
continued medicated treatment therapy. If the physicians use MAT as a form of harm reduction, 
the client may challenge the physician by asking for a taper at a point in their treatment. Instead, 
the physician may disapprove of their request due to them not believing they are ready to 
discontinue and remain abstinent. The physician is thought to have the best interest in the client. 
However, what happens when the length exceeds and the client is ready, but the physician does 
not allow for it? This question was noticed in two participants who volunteered to be a part of 
this study. One of the participant’s physicians lost their license and resulted in them having to 
begin their taper themselves. The second participant had to challenge their physician by asking 
for a taper, leading them to begin tapering themselves. The hopes of this situation remain that 
they take their recovery into their own hands, allowing themselves to taper themselves and 
eventually discontinue their prescription correctly. 
With an emphasis on the physician, they have increased responsibility for the continued 
prescription over the time clients are prescribed. Regarding client thoughts, why would 
withdrawals be more severe from those on MAT than those discontinuing drugs such as heroin 
or fentanyl? Is this due to the purity levels associated with methadone? However, suboxone 
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cannot be attributed to that conclusion due to the ceiling effect it obtains. Due to it being an 
antagonist, it makes it harder for a user to abuse the drug. It still is questioned why would 
withdrawals associated with suboxone be increasingly worse then? It is thought to be attributed 
to a monetary value to replace an illicit drug with a prescription that will guarantee paid 
fulfillment through insurance. If a physician were to use the notion of harm reduction for the 
approach, it would make sense to provide the education as explained earlier to decrease their risk 
levels of relapse and continued use. Ethical dilemmas are flagged where beneficence and non-
maleficence are concerned. Beneficence being an oath that the physician does good for their 
clients and non-maleficence may then be concerned to where the physician takes an additional 
oath to do no harm. Indeed, physicians may have good intentions, but may break these oaths 
when making the wrong decision and not providing therapeutic services. Lastly, over the years, 
the number of waivers has increased for physicians to maintain clients. It can view this from two 
perspectives. Again, one is a monetary increase for the physician and two for an increase in 
helping those diagnosed with an opioid use disorder. Whichever lens one wants to look through, 
the ending conclusion would hope to be focused on eventually discontinuing their prescription to 
help clients live a non-medicated dependent life. 
 To provide appropriate services and follow guidelines mentioned in Chapter II, 
physicians should consider administering the COWS screening tool to evaluate the client for 
stability and ensure they are not abusing their prescription. Treatment goals should also be 
heavily considered upon initial assessment to determine which approach is appropriate for them 
individually. Deciding whether harm reduction or abstinence is the long-term goal will allow the 
physician to meet the client where they are at and provide effective therapeutic services. The 
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clinician should also maintain self-education on the MAT they are prescribing to ensure they are 
up to date on the most effective way to treat those with this detrimental substance use disorder.  
          Although the responsibility of remaining on medication for opioid use disorder is amongst 
both physician and client, it can be concluded it is solely up to the client whether or not they stay 
on the medication or not. However, if the client wishes to discontinue treatment, they may, have 
an increased risk of relapse and withdrawals. They may also taper themselves off the prescription 
they receive and avoid those side effects without the help of their physician and not continue a 
life tied to a medication. Contrarily, the client may also choose to continue their treatment due to 
the security of having a continuous prescription of opiate medications to fuel their addiction 
without the risk of overdosing and an increase in purity of the drug. The client may view this as a 
benefit to maintaining their addiction with the low cost of obtaining the medication. They also 
have the security of knowing they may never have to experience withdrawals due to the 
continued prescription. Unlike when using street drugs, they have to go through the struggle of 
having enough money to obtain it, along with finding a dealer who has some at the time of need. 
Clients are not court-ordered to maintain prescription, so remaining on the prescription is the 
bottom line in their hands. They have the right to choose to continue or discontinue their 
prescription. 
           To conclude the research discoveries and thoughts pertaining, there was not enough 
participant data to develop a clear understanding of who may be held accountable when clients 
are prescribed MAT for OUD. It is thought that with proper education and counseling while 
prescribed the medications, one may have greater chances of decreasing the time spent on 
medicated assisted therapy and live a life independent from opioids. Decreasing time and being 
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on medications will help the client achieve their goal of complete abstinence, and for those who 
believe their recovery does not fully begin once they are off MAT.  
Limitations 
The limitations of this study are as follows. The study consists of using a limited number 
of five participants, with only one methadone perspective. Since this is a qualitative study, 
acquiring data from many of the opioid use population would require an intense amount of time 
and research. The small number of participants contain different demographics – specific opioid 
choice in their addiction, treatment methods they acquired, length of initial addiction, treatment 
duration, and whether they received counseling. Furthermore, participants may withhold 
information due to personal reasons that may affect data. Lastly, it is essential to note that some 
participants have a personal relationship with the researcher, which may influence data. 
However, researcher bias is taken heavily into consideration to avoid alterations of results and 
conclusions. This study also only included participants from a Caucasian ethnicity and did not 
include participants from different cultures. 
Participants with different characteristics hold limitations by obtaining different 
perceptions and viewpoints of substance use and abuse. With a small number of participants, the 
opportunity of obtaining more data to derive a concrete conclusion limits the findings. Each 
participant received their drug of choice, limiting the study by the treatment methods to one 
specific opioid. Meaning one participant may use heroin as their illicit choice and methadone as 
their treatment method. In contrast, another could use oxycodone for their addiction and 
buprenorphine as their treatment.  
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Along with the different illicit and treatment choices, participants differ from the 
addiction and the duration of treatment methods. One participant may come from a history of 
substance abuse for ten years, whereas another only a single year. The course of addiction limits 
the findings for the treatment method's tapering effect and length of treatment. Since one 
participant may show long-term addiction over another, this could determine the success of the 
treatment. Along with the duration of the habit, the course of treatment has significance for a 
limitation. A participant's success rate could be different from others due to their treatment 
length, relying on physical dependence. Those who have completed treatment in the previous 
year might offer different experiences and opinions than those who are currently prescribed, in 
addition to those who have been prescribed for more extended periods of time. 
Results may be affected due to the years the participants were prescribed MAT. 
Participants may have different opinions regarding their treatment due to obtaining a physician 
with possibly less education on prescribing MAT compared to those currently prescribed. 
Current physicians may obtain greater knowledge regarding the effects, proper dosing, and 
treatment protocol compared to those prescribing the medications when there was not much 
information about adequate services. 
Lastly, participants are encouraged to disclose information regarding their addiction and 
treatment, including their feelings, experiences, and other information. What limits this specifier 
is that participants can withhold some variables from the interviewer based on personal reasons. 
Reasonings may include fear of judgment and legal concerns associated with their addiction. 
Traumatic experiences may not be discussed with flashbacks of their use and treatment, causing 
a relapse trigger. 
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In addition to the participant's limitations, this study also lacks current prescribers' 
thoughts and experiences. This limitation may cause a bias against prescribers due to only 
information data from the receiving parties. This limitation is acknowledged when conducting 
research being the bias concern associated with that piece of information. Research from 
previous studies regarding physicians' experiences has provided an analysis with enough 
information to gather a general notion of their knowledge. Furthermore, the years the participants 
were prescribed can alter the opinions regarding the treatment. Those prescribed when suboxone 
first received FDA approval may have received a less educated physician than those who have 
received a physician later, who have more education and understanding of the risks, benefits, and 
how to administer the medications properly. 
Admittingly, this study has various limitations; the data provided is a steppingstone for 
future research. The study developed numerous questions for the researcher to continue 
exploration within this field of study. The treatment of opioid use disorder develops serious 
questions about medications, treatment length, physician's role, the client's role, and approaching 
this severe crisis the world is facing. As the medical field continues developing alternative 
understandings of mental health alongside addiction, physicians, doctors, therapists, and 
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